Výsledky vyhledávání - "Martina A. Sersch"

Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer

Autor: Elizabeth Fox, Michael Berntgen, Alfonso Quintás-Cardama, Veronique Minard-Colin, Susan L. Weiner, André Baruchel, Laura Pearce, Karsten Nysom, Andrew D.J. Pearson, Danielle H. Taylor, Christian M. Zwaan, Nirali N. Shah, Yousif Matloub, Ivan D. Horak, Gregory H. Reaman, Gilles Vassal, Koen Norga, Claudia Rossig, Dominik Karres, Lori A. Ehrlich, Martina Schüßler-Lenz, Alberto S. Pappo, Joe McDonough, Martina A. Sersch, Nick Richardson, Donna Ludwinski, Abraham Bassan, Eric Bleickardt, Nicole Scobie, Stephen Gottschalk, Rob Pieters, Sarah K. Tasian, Courtney Johnson, Teresa de Rojas, Malcolm A. Smith, Franca Ligas, Lynley V. Marshall, Shannon L. Maude, Brenda J. Weigel, Nick Bird, Najat Bouchkouj, Behzad K. Masouleh, Sarah Beaussant Cohen, Delphine Heenen, Rosanna Ricafort, G. Lesa, Linda Hanssens, Peter F. Bross, Carrie Brownstein, Crystal L. Mackall, Martin Pule, Douglas S. Hawkins, Jaroslav Sterba, Maksim Mamonkin

Publikováno v: European Journal of Cancer. 160:112-133

The seventh multi-stakeholder Paediatric Strategy Forum focused on chimeric antigen receptor (CAR) T-cells for children and adolescents with cancer. The development of CAR T-cells for patients with haematological malignancies, especially B-cell precu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::109dc83dd17c2fd2077a3e812e4df67f
https://doi.org/10.1016/j.ejca.2021.10.016

Zobrazit plný text záznamu

Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration

Autor: Andrew Dj, Pearson, Claudia, Rossig, Crystal, Mackall, Nirali N, Shah, Andre, Baruchel, Gregory, Reaman, Rosanna, Ricafort, Delphine, Heenen, Abraham, Bassan, Michael, Berntgen, Nick, Bird, Eric, Bleickardt, Najat, Bouchkouj, Peter, Bross, Carrie, Brownstein, Sarah Beaussant, Cohen, Teresa, de Rojas, Lori, Ehrlich, Elizabeth, Fox, Stephen, Gottschalk, Linda, Hanssens, Douglas S, Hawkins, Ivan D, Horak, Danielle H, Taylor, Courtney, Johnson, Dominik, Karres, Franca, Ligas, Donna, Ludwinski, Maksim, Mamonkin, Lynley, Marshall, Behzad K, Masouleh, Yousif, Matloub, Shannon, Maude, Joe, McDonough, Veronique, Minard-Colin, Koen, Norga, Karsten, Nysom, Alberto, Pappo, Laura, Pearce, Rob, Pieters, Martin, Pule, Alfonso, Quintás-Cardama, Nick, Richardson, Martina, Schüßler-Lenz, Nicole, Scobie, Martina A, Sersch, Malcolm A, Smith, Jaroslav, Sterba, Sarah K, Tasian, Brenda, Weigel, Susan L, Weiner, Christian Michel, Zwaan, Giovanni, Lesa, Gilles, Vassal

Publikováno v: European journal of cancer
European journal of cancer, 160:112-133

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::7e4b2ff665e9b497893f3198ef4554c2
https://repository.uantwerpen.be/docstore/d:irua:12922

Zobrazit plný text záznamu

Long-term follow-up results of a multicenter first-in-human study of the dual BCMA/CD19 Targeted FasT CAR-T GC012F for patients with relapsed/refractory multiple myeloma

Autor: Lianjun Shen, Yi Zhao, Jian Ge, Li Gao, Baoxia Dong, Martina A. Sersch, Hua Zhang, Xun Ye, Jia Liu, Hua Jiang, Weijun Fu, Xiequn Chen, Jing Lu, Aili He, Lu Li, Li Liu

Publikováno v: Journal of Clinical Oncology. 39:8014-8014

8014 Background: The dual CAR-T GC012F developed on the novel FasT CAR-T platform targeting B cell maturation antigen (BCMA), and CD19 was designed to improve depth of response and overall efficacy for CAR-T as therapy for Multiple Myeloma. Here, we

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3af38202feb88409fc967fe658c3e235
https://doi.org/10.1200/jco.2021.39.15_suppl.8014

Zobrazit plný text záznamu

Lower Exposure and Faster Clearance of Bevacizumab in Gastric Cancer and the Impact of Patient Variables: Analysis of Individual Data from AVAGAST Phase III Trial

Autor: Mauricio Maia, Jin Jin, David E. Allison, John B. Lowe, Kelong Han, Martina A. Sersch

Publikováno v: The AAPS Journal

Altered pharmacokinetics of antibody drugs has been reported in advanced gastric cancer (AGC). We aim to evaluate bevacizumab pharmacokinetics in AGC from the Phase III trial (AVAGAST), and explore the influence of patient variables. Bevacizumab conc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5fe52bcaf14730c026f384a85219f33
https://doi.org/10.1208/s12248-014-9631-6

Zobrazit plný text záznamu

Efficacy and Safety of Treatment with Bevacizumab (BEV) + Chemotherapy (CT) Beyond First Progression in Patients (PTS) with Metastatic Colorectal Cancer (MCRC) Previously Treated with BEV + CT: Age Subgroup Analysis From a Randomised Phase III Intergroup Study (ML18147)

Autor: Jaafar Bennouna, Martina A. Sersch, Irmarie Reyes-Rivera, T. Andre, R. von Moos, Claus-Christoph Steffens, O. Bouche, P. Österlund, Dirk Arnold, Javier Sastre

Publikováno v: Annals of Oncology. 23:ix190-ix191

Background The ML18147 study showed that BEV + standard CT as second-line treatment for pts with mCRC who progressed after first-line BEV-containing CT significantly improved survival with an acceptable toxicity profile. However, more evidence is nee

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::373bb8a29e47494f7860abcc08532e01
https://doi.org/10.1016/s0923-7534(20)33169-0

Zobrazit plný text záznamu

Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first disease progression (PD) in patients with metastatic colorectal cancer (mCRC) previously treated with BEV-based therapy: Outcomes according to KRAS status and first-line CT backbone in the ML18147 study

Autor: S. Osborne, Martina A. Sersch, Javier Sastre, Eric Van Cutsem, Jaafar Bennouna, Stefan Kubicka, Roger von Moos, Priti S. Hegde, Richard Greil, Pia Österlund, Thierry André, Dirk Arnold, Frank Hermann

Publikováno v: Journal of Clinical Oncology. 32:520-520

520 Background: ML18147 is the first randomized phase III study to show that continuing BEV + standard CT as second-line (2L) treatment significantly improves overall survival (OS) and progression-free survival (PFS) in patients with mCRC who progres

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::82b5c2f0c4a53edb002f0ad7d8332f61
https://doi.org/10.1200/jco.2014.32.3_suppl.520

Zobrazit plný text záznamu

Exposure and clearance of bevacizumab in patients with first-line advanced gastric cancer

Autor: Mauricio Maia, Kelong Han, Martina A. Sersch, Jin Jin, David E. Allison

Publikováno v: Journal of Clinical Oncology. 31:2603-2603

2603 Background: Bevacizumab (BEV), rhuMAB VEGF, in combination with chemotherapy (CT) is currently approved in various types of cancer. Recently, BEV+CT was evaluated in 1st line advanced gastric cancer (AGC) in a double-blind randomized phase 3 tri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7cec2fcd8e9c5ec484103a1452c0ddb1
https://doi.org/10.1200/jco.2013.31.15_suppl.2603

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání